Identification of therapy-resistant cells driving relapse in Medulloblastoma from integrated spatial transcriptomics and tissue imaging

通过整合空间转录组学和组织成像鉴定导致髓母细胞瘤复发的耐药细胞

• 批准号: nhmrc : 2001514
• 金额: $ 74.93万
• 依托单位国家: 澳大利亚
• 项目类别: Ideas Grants
• 财政年份: 2021
• 资助国家: 澳大利亚
• 起止时间: 2021-01-01 至 2024-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/identification-therapy-resistant-tissue-imaging/1779792
• 关键词: Identification; therapy; resistant; cells; driving

Medulloblastoma (MB) is the most common cause of cancer related mortality in children, with relapsed MB nearly a universally fatal event. Relapsed MB can be caused by pre-existing rare cells that escape treatment and continue to evolve. This project will identify the organisation of all cell types within patient derived xenograft models of MB, monitoring how this changes throughout tumour progression and drug treatment. We will identify rare cells responsible for driving recurrence.

髓母细胞瘤（MB）是儿童癌症相关死亡的最常见原因，MB复发几乎是普遍致命的事件。复发性MB可能是由预先存在的罕见细胞引起的，这些细胞逃避治疗并继续进化。该项目将确定MB患者来源的异种移植模型中所有细胞类型的组织，监测其在肿瘤进展和药物治疗过程中的变化。我们将确定负责驱动复发的罕见细胞。